CoChat

Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States

Amin, Alpesh, Bruno, Amanda, Trocio, Jeffrey, Lin, Jay, Lingohr-Smith, Melissa · 2016 · Clinical and Applied Thrombosis/Hemostasis

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Objective: Real-world medical cost avoidances from a US payer perspective were estimated when new oral anticoagulants (NOACs) are used instead of warfarin for the treatment of patients with venous thromboembolism (VTE). Methods: Reductions in real-world event rates of recurrent VTE and MB were obtained by applying rate reductions from the NOACs versus warfarin trials to the Worcester population. Incremental annual medical costs among patients with VTE and MB from a US payer perspective were obtained from the literature or claims databases. Differences in total medical costs for patients treated with NOACs versus warfarin were then estimated. Univariate and Monte Carlo sensitivity analyses were additionally carried out. Results: The annual total medical cost avoidances versus warfarin were greatest for VTE patients treated with apixaban (−US$4440 per patient-year [ppy]), followed by those treated with rivaroxaban (−US$2971 ppy), edoxaban (−US$1957 ppy), and dabigatran (−US$572 ppy). The medical cost avoidances remained consistent under sensitivity analyses. Conclusion: Based on real-world data, when any of the evaluated NOACs are used instead of warfarin for treatment of patients with acute VTE, annual medical costs are reduced. Of the NOACs, apixaban has the greatest real-world medical cost avoidance, as its use is associated with substantial reductions in both VTE and MB event rates.

Overview

Integrity signals

Registry

Crossref · 10.1177/1076029615585991

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 2

  1. White Paper. Deep vein thrombosis. Advancing awareness to protect patient lives. Public Health Leadership Conference on Deep-Vein Thrombosis, American Public Health Association; 2003. Web site. http://www.apha.org/NR/rdonlyres/A209F84A-7C0E-4761-9ECF-61D22E1E11F7/0/DVT_White_Paper.pdf. Accessed February 1, 2015.
  2. Amin A, 2015, J Med Econ

Cited by

See all 20

Metadata

Authors
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M.
Affiliations
  • University of California, Irvine (US)
  • Bristol-Myers Squibb (United States) (US)
  • Pfizer (United States) (US)
  • Novosys Health, Health Economics & Outcomes Research, Green Brook, NJ, USA
Corresponding author
Amin, Alpesh
Venue
Clinical and Applied Thrombosis/Hemostasis
Published
2015-05-19
Volume
22
Issue
1
Pages
5-11
ISSN
  • 1076-0296 (ISSN-L)
  • 1938-2723
OpenAlex
W1847190482
Cited by
20
References
17
Citations by year
2025: 1 · 2023: 2 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 1
FWCI
3.73
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Clinical and Applied Thrombosis/Hemostasis (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
direct oral anticoagulants, warfarin, venous thromboembolism, apixaban, rivaroxaban, edoxaban, dabigatran, major bleeding, recurrent venous thromboembolism, payer perspective
MeSH terms
Administration, Oral, Anticoagulants, Costs and Cost Analysis, Humans, Monte Carlo Method, United States, Warfarin, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. https://app.cochat.ai/papers/10.1177/1076029615585991
The paper
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016). Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029615585991

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.